A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies

Phase 1 Completed 49 enrolled Innovent Biologics (Suzhou) Co. Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy in patients with advanced malignancies.

Timeline

Start: 2019-01-10
Primary completion: 2022-02-16
Completion: 2022-02-16

Publications

Cai S, Wei X, Li Q, Jiang Z, Li L. Smart materials in pharmacological drug development: Neutrophils and its constituents for drug delivery and consequent antitumor effects. Mol Immunol. 2025 Jul;183:18-32. doi: 10.1016/j.molimm.2025.04.010. Epub 2025 May 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IBI188	Monoclonal antibody	0.1 mg/kg	Intravenous
Subject	IBI188	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	IBI188	Monoclonal antibody	1 mg/kg	Intravenous
Subject	IBI188	Monoclonal antibody	10 mg/kg	Intravenous
Subject	IBI188	Monoclonal antibody	20 mg/kg	Intravenous
Subject	IBI188	Monoclonal antibody	30 mg/kg	Intravenous
Subject	IBI188	Monoclonal antibody	45 mg/kg	Intravenous

A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies

Summary

Timeline

Publications

Drugs

Indications